Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Osiris Therapeutics, Inc. Receives Marketing Clearance From Health Canada For Prochymal


Thursday, 17 May 2012 04:36pm EDT 

Osiris Therapeutics, Inc. announced that it has received market authorization from Health Canada to market its stem cell therapy Prochymal(remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. Prochymal was authorized under Health Canada's Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing. 

Company Quote

13.18
0.19 +1.46%
4:00pm EDT